Former U.S. President Donald Trump is reported to have instructed the acceleration of research on hallucinogenic drugs. The intent behind this move, as stated, is to explore potential mental health benefits and treatment possibilities that these substances might offer. Details surrounding the extent of the research and the substances involved remain unclear.

In Japan, the use and possession of illegal substances including hallucinogenic drugs are strictly regulated, often leading to significant legal penalties. Despite this stringent stance, the country shows continued interest in novel mental health treatments, including those involving controlled substances under rigorous scientific conditions.

In contrast to Japan, both the US and EU have seen a resurgence of interest in psychedelic research, particularly for mental health treatments. A growing number of studies and clinical trials investigating the potential benefits of substances such as psilocybin and MDMA are taking place, although they remain heavily regulated.